Association of immune parameters with clinical outcome in stage III colon cancer: Results of Southwest Oncology Group protocol 9009

Cancer Immunology Immunotherapy

Volumn 48, Issue 9, 1999, Pages 533-539

  Holcombe, Randall F ^a   Jacobson, Joth ^b   Dakhil, Shaker R ^c   Stewart, Ruby M ^d   Betzing, Kenneth S ^d   Kannan, Krishna ^d   Macdonald, John S ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SW Oncol Group Statistical Center   (United States)

^c WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^d LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^e ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

Levamisole; Lymphocyte phenotype; Natural killer cells; Tumor immunology

Indexed keywords

FLUOROURACIL; LEVAMISOLE;

ARTICLE; CANCER IMMUNOLOGY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL COUNT; CELLULAR IMMUNITY; CLINICAL ARTICLE; COLON CANCER; FOLLOW UP; HUMAN; LYMPHOCYTE; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT;

EID: 0032718175     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050602     Document Type: Article

References (25)

1. + T cell subsets. Immunol Rev 123:5-22
2. 2. Brabander M de, Cree J de, Vandebroek J, Verhaegen H, Janssen PAJ (1992) Levamisole in the treatment of cancer: anything new? Anticancer Res 12:177-188
3. 3. Brabander M de, Vandebroek J, Wassenaar H, DeCree J, Braisier A, Demoen B, DeRidder R, Jagers E, Roels V, Vogels O (1995) Immunological alterations induced by adjuvant treatment of postoperative colon carcinoma Duke's B or C with levamisole in combination with 5-FU. Anticancer Res 15:2271-2277
4. 4. Chrisp P, McTavish D (1991) Levamisole/fluorouracil: a review of their pharmacology and adjuvant therapeutic use in colorectal cancer. Drugs Aging 4:317-337
5. 5. Holcombe RF, Stewart RM (1997) Augmentation of IL12-dependent Th1 cytokine production by levamisole. Allergy Clin Immunol Int 9:119-120
6. 6. Holcombe RF, Stewart RM, Betzing KW, Kannan K (1994) Alteration in lymphocyte phenotype associated with administration of adjuvant levamisole and 5-fluorouracil. Cancer Immunol Immunother 34:394-398
7. + T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547-549
8. 8. Janik J, Kopp WC, Smith JW, Longo DL, Alvord G, Sharfman WH, Fenton RG, Sznol M, Steis RG, Creekmore SP, Ewel CH, Hursey J, Urba WJ (1993) Dose-related immunological effects of levamisole in patients with cancer. J Clin Oncol 11:125-135
9. 9. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Statist Assoc 53:457-481
10. 10. Kovach JS, Svingen PA, Schaid DJ (1992) Levamisole potentiation of fluorouracil antiproliferative activity mimicked by orthovanadate, an inhibitor of tyrosine phosphatase. J Natl Cancer Inst 84:515-519
11. 11. Laurie JA, Moertel CG, Fleming TR, Wiegand HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, Malliard J, Twito DI, Morton RF, Tschetter LK, Barlow JF (1989) Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 7:1447-1456
12. 12. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, Trinchieri G, Romagnani S (1993) Natural killer cell stimulatory factor (interleukin 12 [IL12]) induces T helper type 1 [Th1]-specific immune responses and inhibits the development of IL4 producing Th cells. J Exp Med 177:1199-1204
13. 13. Marimoto, Chikao (1995) CD45 cluster report. In: Schlossman SF, et al (eds) Leucocyte typing. V. Oxford University Press, New York, pp 386-389
14. 14. McKnight AJ, Zimmer GJ, Fogelman I, Wolf SF, Abbas A (1994) Effects of IL12 on helper T cell dependent immune responses in vivo. J Immunol 152:2172-2179
15. 15. Moertel CG, Fleming TR, McDonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH, Mailliard JA (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358
16. 16. O'Connell MJ, Kahn MJ, Erlichman C, Goldberg RM, Shepherd LE (1996) Optimal duration of fluorouracil plus levamisole colon cancer surgical adjuvant therapy. J Clin Oncol 10:2887
17. 17. O'Connell MG, Laurie JA, Shepherd LE (1996) A prospective evaluation of chemotherapy duration and regimen as surgical adjuvant treatment for high-risk colon cancer: a collaborative trial of North Central Cancer Treatment Group and the National Cancer Institute of Canada Clinical Trials Group. Proc Am Soc Clin Oncol 15:209a
18. 18. O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ, Erlichman C, Shepherd L, Moertel CG, Kocha WI, Pazdur R, Wiand S, Rubin J, Vukov AM, Donohue JH, Krook JE, Figueredo A (1998) Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16:295-300
19. 19. Renoux G, Renoux M (1971) Effet immunostimulant d'un imidothiazole dans l'immunisation des souris contre l'infection par Brucella abortus. CR Acad Sci Ser D Sci Nat 272:349-350
20. 20. Rudd CE, Morimoto C, Wong LL, Schlossman SF (1987) The subdivision of the T4 (CD4) subset on the basis of the differential expression of L-C/T200 antigens. J Exp Med 166:1758-1773
21. 21. Schiller JH, Lindstom M, Witt PL, Hank JA, Mahvi D, Wagner RJ, Sondel P, Borden EC (1991) Immunological effects of levamisole in vitro. J Immunol 10:297-306
22. 22. Spreafico F (1980) Use of levamisole in cancer patients Drugs 19:105-116
23. 23. Trinchieri G (1993) Interleukin-12 and its role in the generation of Th1 cells. Immunol Today 14:335-338
24. 24. Tripodi D, Parks LC, Brugmans J (1973) Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer. N Engl J Med 289:354-357
25. 25. Windle R, Bell PRF, Shaw D (1987) Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 74:569-572